Impax v. Dr. Reddy’s: RYTARY Patent Dispute Settled After 207 Days
Impax Laboratories filed suit in the District of New Jersey against Dr. Reddy’s Laboratories over five patents covering its RYTARY extended-release carbidopa/levodopa capsules. The parties reached a confidential settlement and voluntarily dismissed all claims without prejudice after 207 days, with each side bearing its own legal costs.
RYTARY generic entry dispute resolved by confidential settlement
On 18 July 2024, Impax Laboratories, LLC filed an infringement action in the District of New Jersey (Case No. 2:24-cv-07875) against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. The complaint asserted five patents — US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2 — covering Impax’s RYTARY extended-release carbidopa/levodopa capsules across four dosage strengths (23.75/95 mg, 36.25/145 mg, 48.75/195 mg, and 61.25/245 mg). The trigger was Dr. Reddy’s filing of an ANDA or comparable regulatory pathway seeking to launch competing extended-release carbidopa/levodopa capsules in the US market.
The case closed on 10 February 2025 — 207 days after filing — via a stipulated voluntary dismissal without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii). Both parties agreed to settle on undisclosed terms. The court retained jurisdiction to enforce the settlement agreement. Critically, the dismissal is without prejudice, meaning the patents remain enforceable and Impax retains the legal right to reassert them should any breach of the settlement occur or a new infringement action arise.
The 207-day resolution is notably swift for pharmaceutical patent litigation of this complexity, suggesting the parties may have reached a licensing or entry-date agreement relatively early in discovery. The absence of claim construction proceedings or substantive merits rulings means no public record exists clarifying the scope of the five asserted patents. What drove settlement — whether commercial economics, patent validity concerns, or a negotiated launch date — remains entirely confidential.
Filing to Voluntary dismissal in 207 days
207 days — faster than the median ANDA-linked Hatch-Waxman district court case, suggesting early settlement momentum
Voluntarily dismissed: what the settlement structure means for both parties
Rule 41(a)(1)(A)(ii): stipulated dismissal without prejudice
A Rule 41(a)(1)(A)(ii) dismissal requires a signed stipulation from all appearing parties. ‘Without prejudice’ means the claims are extinguished only for this proceeding — Impax is not barred from filing again on the same patents. The court retaining jurisdiction to enforce the settlement agreement is a standard but meaningful addition, giving either party a direct enforcement path without filing a new action.
No merits adjudicationWithout prejudice — but the public record is silent on full terms
The stipulation specifies dismissal ‘without prejudice’, preserving Impax’s right to re-file if settlement terms are breached. A ‘with prejudice’ dismissal would permanently bar re-litigation of these claims — that did not happen here. The underlying settlement agreement is confidential; whether it includes a licensed launch date, royalty payments, or a covenant not to sue is not disclosed in any public filing.
Settlement terms undisclosedImpax retains enforceability across all five patents
The without-prejudice dismissal leaves all five asserted patents — US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2 — fully enforceable. No adverse claim construction or validity ruling was entered. Impax can assert these patents against other generic filers or, if Dr. Reddy’s breaches the settlement, re-litigate against DRL directly via the retained court jurisdiction.
Patents intact and enforceableDr. Reddy’s market entry terms governed by confidential agreement
Dr. Reddy’s avoided a litigated validity or infringement finding, which typically signals a negotiated resolution — possibly a future authorised entry date or licensed launch. The mutual cost-bearing provision suggests neither party extracted a clear litigation win. Any agreed launch date or royalty obligation will shape the competitive dynamics for carbidopa/levodopa ER generics in the US market, but those specifics remain off the public record.
Entry terms undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Impax Laboratories, LLC | Company | Specialty pharma company — holder of US8557283B2 and four related RYTARY ER capsule patentsSearch in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian generic pharmaceutical manufacturer and its US subsidiary seeking to market carbidopa/levodopa ER capsulesSearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Stephanie L. Jonaitis | Attorney | Counsel for Impax Laboratories, LLCSearch in Eureka ↗ |
| Plaintiff law firm | TROUTMAN PEPPER LOCKE LLP | Law Firm | Representing Impax Laboratories, LLCSearch in Eureka ↗ |
| Defendant counsel | Frank D. Rodriguez | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | KIERSTEN AMANDA FOWLER | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal order confirms the parties reached a binding settlement covering all claims, counterclaims, and affirmative defenses. The phrase ‘voluntarily dismissed in its entirety without prejudice’ means no merits determination was made — patent validity, claim scope, and infringement remain unadjudicated. The court’s retention of enforcement jurisdiction is the operative legal mechanism: it converts the private settlement into a court-enforceable obligation without requiring a consent judgment on the merits.
US8557283B2 — RYTARY extended-release carbidopa/levodopa capsule formulations
US8557283B2 (application no. US13/711248) is the anchor patent in a family of five covering Impax’s RYTARY product — an extended-release oral capsule delivering carbidopa and levodopa for the management of Parkinson’s disease. The family extends through US9089608B2, US9463246B2, US9533046B2, and US9901640B2, with applications filed between 2012 and 2016. Together the patents cover formulation composition, methods of use, and dosage-form engineering for multi-layer or bead-based extended-release delivery of the dopaminergic drug combination.
RYTARY occupies a premium position in the Parkinson’s disease treatment market, and its patent estate is a principal barrier to generic competition. The five-patent cluster asserted here means any ANDA challenger must design around or invalidate multiple, overlapping claim sets — a costly and uncertain undertaking. For competitors in CNS drug delivery, the breadth of the family across composition and method claims creates substantial freedom-to-operate exposure even for formulation approaches that nominally differ from RYTARY’s commercial embodiment.
Should your team run an FTO analysis against the RYTARY patent family?
Any pharmaceutical company developing or acquiring extended-release carbidopa/levodopa capsule products — whether for ANDA filing, 505(b)(2) application, or novel formulation development — faces material infringement risk from this five-patent family. The patents span composition, method, and dosage-form claims, meaning a product can potentially infringe even if its precise formulation differs from RYTARY. The confidential settlement in this case provides no claim construction guidance, leaving scope boundaries entirely unresolved.
PatSnap Eureka’s FTO Search Agent can map each of the five asserted patents against your product’s formulation parameters, identify file-wrapper prosecution history that may narrow claim scope, and flag prior art potentially relevant to validity challenges. Given that no court has construed these claims, a thorough FTO with claim-by-claim analysis is essential before any ANDA filing or extended-release CNS formulation programme advances to clinical or regulatory stage.
Run a freedom-to-operate analysis on US8557283B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman carbidopa/levodopa patent cases in D.N.J.
Explore patent infringement actions in D.N.J. involving extended-release CNS drug formulations and ANDA challenges to branded Parkinson’s disease therapies.
What this case signals for the carbidopa/levodopa ER patent landscape
Five-patent Hatch-Waxman settlements rarely end at day 207 without substantive skirmishing — here is what that pace reveals.
Dense patent clusters around RYTARY create high barriers for generic entry
Impax holds at least five granted US patents across formulation, composition, and method claims for carbidopa/levodopa ER capsules. Generic filers challenging RYTARY face a multi-front invalidity burden. Any ANDA applicant should conduct thorough FTO analysis across all five patents before projecting a commercial launch timeline.
Swift settlement signals commercial pragmatism, not patent weakness
A 207-day resolution before substantive motion practice typically suggests the parties found a commercially acceptable middle ground — often a negotiated entry date — rather than either side identifying a decisive legal advantage. Patent holders and generic challengers in the CNS drug space should monitor consent judgment filings for any disclosed launch date terms.
Impax v Dr. — key questions answered
Impax asserted five patents: US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2. All five cover aspects of RYTARY extended-release carbidopa/levodopa capsules, including formulation composition and methods of use. The case was filed in the District of New Jersey on 18 July 2024 and closed via settlement on 10 February 2025.
Dismissal without prejudice under Rule 41(a)(1)(A)(ii) means no merits ruling was entered and all five patents remain fully enforceable. Impax retains the right to assert the same patents against Dr. Reddy’s if the settlement is breached, or against other generic filers. The court also retained jurisdiction to enforce the confidential settlement agreement.
No. The case settled and was voluntarily dismissed after 207 days, before any substantive merits proceedings such as claim construction or summary judgment. The scope of the five asserted RYTARY patents remains unadjudicated, which is significant for other ANDA filers assessing freedom-to-operate risk.
RYTARY (carbidopa/levodopa) is an extended-release capsule approved for Parkinson’s disease, marketed by Impax Laboratories. Its patent estate — at least five granted US patents spanning formulation and method claims — is a key barrier to generic competition. Generic filers face a multi-patent invalidity challenge, and the confidential settlement in this case means no public claim construction guidance exists to assist in FTO analysis.
Impax was represented by Stephanie L. Jonaitis of Troutman Pepper Locke LLP. Dr. Reddy’s was represented by Frank D. Rodriguez and Kiersten Amanda Fowler of Windels Marx Lane & Mittendorf, LLP. The case was litigated in the District of New Jersey.
PatSnap Eureka searches patents and litigation data to answer instantly.